scholarly journals Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

2020 ◽  
Vol 20 (2) ◽  
pp. 45-55
Author(s):  
K Prso ◽  
N Zidekova ◽  
M Dohal ◽  
I Porvaznik ◽  
M Prso ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Plasma Drug Concentration ◽  
Therapeutic Drug ◽  
Plasma Drug ◽  
Therapeutic Level ◽  
First Line ◽  
Antituberculosis Drugs ◽  
Health Related

AbstractTuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible Mycobacterium tuberculosis strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.

scholarly journals Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study

2021 ◽  
Vol 10 (22) ◽  
pp. 5396
Author(s):  
Grzegorz Grześk ◽  
Wioleta Stolarek ◽  
Michał Kasprzak ◽  
Elżbieta Grześk ◽  
Daniel Rogowicz ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Therapeutic Range ◽  
Drug Monitoring ◽  
First Generation ◽  
Suicide Attempts ◽  
Anticonvulsant Drug ◽  
Therapeutic Drug ◽  
Therapeutic Level ◽  
Suspected Drug

Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011. The method used for the determination of the CBZ concentration was fluorescence polarization immunoassay (FPIA) performed using an Abbott GmbH TDx automatic analyzer, with the therapeutic range for carbamazepine being 4–12 µg/mL. Results: The therapeutic range was observed more often in patients between 3 and 17 years of age compared with the population ≥18 years of age (73.5% vs. 68.8%). The therapeutic level was exceeded less frequently in the population between 3 and 17 years of age despite them being given a significantly higher dose per kilogram of body weight than in the population ≥18 years of age (13.64 mg/kg vs. 10.43 mg/kg, p < 0.0001). Patients ≥18 years of age were statistically significantly more likely to be in the group with a suspected drug overdose (73.9% vs. 26.1%), and suicide attempts only occurred in elderly patients (100.0% vs. 0.0%, p = 0.003). Conclusion: The results of the TDM of CBZ showed that only 71% of all samples were at the therapeutic level. To ensure the maximum efficacy and safety of the therapy, it is necessary to monitor the concentration of CBZ regardless of sex and age.

scholarly journals Successful determination of imatinib dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction.

2021 ◽  
Author(s):  
Ryosuke Nakahara ◽  
Takahiro Sumimoto ◽  
Ryota Tanaka ◽  
Masao Ogata ◽  
Hiroki Itoh
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Renal Dysfunction ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug ◽  
First Line ◽  
Acute Renal Dysfunction ◽  
First Line Treatment

Imatinib is used as first-line treatment for chronic myeloid leukemia (CML) even in patients with impaired renal function. We successfully used therapeutic drug monitoring to determine the dose for re-administration of imatinib in a CML patient who initiated dialysis for acute renal dysfunction associated with the initial imatinib therapy.

Sign in / Sign up

Export Citation Format

Share Document